Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
Executive Summary
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
You may also be interested in...
$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map
In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.
Pipeline Watch: Phase III Readouts For Asciminib, Tesetaxel And Palovarotene
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit
Intercept and Axcella provide updated data on their NASH programs at the International Liver Conference, while CymaBay offers the full dataset for seladelpar in PBC.
Need a specific report? 1000+ reports available
Buy Reports